RNA-Binding Proteins and Translation in Neurodegenerative Disease
Standard
RNA-Binding Proteins and Translation in Neurodegenerative Disease. / Duncan, Kent.
The Oxford Handbook of neuronal Protein Synthesis. Hrsg. / Wayne S. Sossin. 1. Aufl. Oxford University Press, 2020. S. 1-48.Publikationen: SCORING: Beitrag in Buch/Sammelwerk › SCORING: Beitrag in Sammelwerk › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - CHAP
T1 - RNA-Binding Proteins and Translation in Neurodegenerative Disease
AU - Duncan, Kent
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Both RNA-binding proteins (RBPs) and translation are increasingly implicated in several neurodegenerative diseases, but their specific roles in promoting disease are not yet fully defined. This chapter critically evaluates the evidence that altered translation of specific mRNAs mediated by RNA-binding proteins plays an important role in driving specific neurodegenerative diseases. First, diseases are discussed where a causal role for RNA-binding proteins in disease appears solid, but whether this involves altered translation is less clear. The main foci here are TAR DNA-binding protein (TDP-43) and fused in sarcoma (FUS) in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Subsequently, diseases are presented where altered translation is believed to contribute, but involvement of RNA-binding proteins is less clear. These include Huntington’s and other repeat expansion disorders such as fragile X tremor/ataxia syndrome (FXTAS), where repeat-induced non-AUG-initiated (RAN) translation is a focus. The potential contribution of both canonical and non-canonical RBPs to altered translation in Parkinson’s disease is discussed. The chapter closes by proposing key research frontiers for the field to explore and outlining methodological advances that could help to address them.
AB - Both RNA-binding proteins (RBPs) and translation are increasingly implicated in several neurodegenerative diseases, but their specific roles in promoting disease are not yet fully defined. This chapter critically evaluates the evidence that altered translation of specific mRNAs mediated by RNA-binding proteins plays an important role in driving specific neurodegenerative diseases. First, diseases are discussed where a causal role for RNA-binding proteins in disease appears solid, but whether this involves altered translation is less clear. The main foci here are TAR DNA-binding protein (TDP-43) and fused in sarcoma (FUS) in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Subsequently, diseases are presented where altered translation is believed to contribute, but involvement of RNA-binding proteins is less clear. These include Huntington’s and other repeat expansion disorders such as fragile X tremor/ataxia syndrome (FXTAS), where repeat-induced non-AUG-initiated (RAN) translation is a focus. The potential contribution of both canonical and non-canonical RBPs to altered translation in Parkinson’s disease is discussed. The chapter closes by proposing key research frontiers for the field to explore and outlining methodological advances that could help to address them.
U2 - DOI: 10.1093/oxfordhb/9780190686307.013.25
DO - DOI: 10.1093/oxfordhb/9780190686307.013.25
M3 - SCORING: Contribution to collected editions/anthologies
SP - 1
EP - 48
BT - The Oxford Handbook of neuronal Protein Synthesis
A2 - Sossin, Wayne S.
PB - Oxford University Press
ER -
